Insider trade

Gilead Sciences (GILD): Officer exercised options on 23K shares

Johanna Mercier, Officer at Gilead Sciences, reported an option exercise of 23K shares.

23K
Shares · @ $66.64
Traded
Aug 17, 2026
Filed
Aug 18, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 27, 2026CongressDisclosed purchase of GILD — reported range $1,001 - $15,000
  2. May 6, 2026Congress · 1 personMembers of Congress: 2 purchases
  3. Jun 24, 2026FDAFDA drug approval: Trodelvy
  4. Jun 24, 2026FDAFDA drug approval: Trodelvy
  5. Jul 1, 2026Insider · 1 personInsiders: 2 sales (~$1.9M)
  6. Jul 15, 2026Insider · 2 peopleInsiders: 2 sales (~$780K)
  7. Aug 3, 2026Insider · 1 personInsiders: 3 sales (~$2.0M)
  8. Aug 4, 2026Company filing · Form 8-K · ResultsReported its results
  9. Aug 17, 2026Insider · 2 peopleInsiders: 3 sales (~$4.3M)

What came next

  1. Aug 20, 2026Insider · 1 personInsiders: 5 sales (~$725K)
  2. Aug 26, 2026Insider · 1 personInsiders: 4 sales (~$2.7M)
  3. Aug 27, 2026FDAFDA drug approval: Bixlenvo Sunlenca Starter Pack (Copackaged)
  4. Aug 27, 2026FDAFDA drug approval: Sunlenca
  5. Aug 27, 2026FDAFDA drug approval: Bixlenvo
  6. Aug 27, 2026FDAFDA drug approval: Sunlenca
  7. Sep 1, 2026Insider · 1 personInsiders: 3 sales (~$2.2M)
  8. Sep 15, 2026Insider · 2 peopleInsiders: 4 sales (~$869K)
  9. Oct 1, 2026Insider · 1 personInsiders: 2 sales (~$2.2M)
  10. Oct 15, 2026Insider · 2 peopleInsiders: 2 sales (~$937K)
  11. Oct 29, 2026Company filing · Form 8-K · ResultsReported its results
  12. Oct 30, 2026InsiderCEO sold ~$2.78M of GILD shares in the open market
  13. Nov 2, 2026Insider · 1 personInsiders: 5 sales (~$2.5M)
  14. Nov 4, 2026InsiderCEO sold ~$18M of GILD shares in the open market
  15. Nov 5, 2026InsiderCEO sold ~$1.72M of GILD shares in the open market
  16. Nov 6, 2026InsiderOfficer sold ~$558K of GILD shares in the open market
  17. Nov 10, 2026Government · Federal Register noticeNotice Pursuant to the National Cooperative Research and Production Act of 1993-R Consortium, Inc.
  18. Nov 12, 2026Insider · 1 personInsiders: 4 sales (~$1.8M)
  19. Nov 16, 2026Insider · 2 peopleInsiders: 4 sales (~$5.3M)
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Gilead Sciences

For Gilead Sciences, OQRO holds 47 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its GILD page.

Other recent filings by Johanna Mercier, Chief Comm & Corp Aff Officer

The full history of Johanna Mercier, Chief Comm & Corp Aff Officer is on the profile page.

How this filing works

Explore the data

Common questions

Which Gilead Sciences (GILD) insider traded, and how much?

Johanna Mercier, Officer at Gilead Sciences, reported an option exercise of 23K shares. At $66.64.

When did it happen, and when was it made public?

Traded: Aug 17, 2026. Filed: Aug 18, 2026. That is 1 day between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Gilead Sciences recently?

For Gilead Sciences, OQRO holds 47 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the GILD page.

Does this mean GILD stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Gilead Sciences

Everything OQRO holds on this company is on its GILD page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data